Published in Cancer Res on November 01, 2005
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res (2009) 1.87
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO J (2009) 1.23
Functions of MDMX in the modulation of the p53-response. J Biomed Biotechnol (2011) 1.12
MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. PLoS One (2012) 1.06
A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer. Carcinogenesis (2009) 1.03
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk. Hum Mutat (2014) 0.97
MDM4 (MDMX) and its Transcript Variants. Curr Genomics (2009) 0.94
Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis. PPAR Res (2008) 0.93
Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. J Mol Med (Berl) (2008) 0.92
Mdmx promotes genomic instability independent of p53 and Mdm2. Oncogene (2014) 0.91
Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck. Pharmacogenet Genomics (2011) 0.87
Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). J Pharm Biomed Anal (2009) 0.86
Advances in pediatric rhabdomyosarcoma characterization and disease model development. Histol Histopathol (2012) 0.85
Stress-induced isoforms of MDM2 and MDM4 correlate with high-grade disease and an altered splicing network in pediatric rhabdomyosarcoma. Neoplasia (2013) 0.82
Protein-protein interactions for cancer therapy. Proc Natl Acad Sci U S A (2006) 0.81
Protecting the genome from mdm2 and mdmx. Genes Cancer (2012) 0.79
Mutation analysis of the MDM4 gene in German breast cancer patients. BMC Cancer (2008) 0.79
Interacting partners of FEN1 and its role in the development of anticancer therapeutics. Oncotarget (2017) 0.75
Role of MDM2 and MDMX in DNA repair. J Mol Cell Biol (2016) 0.75
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol (2005) 5.07
Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell (2006) 4.10
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol (2009) 3.57
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol (2002) 3.55
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res (2007) 3.12
The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell (2005) 2.45
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol (2011) 2.44
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res (2011) 2.27
MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol Cell (2007) 2.10
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
FIOH-sponsored newsletter misrepresents asbestos hazards in Zimbabwe. Int J Occup Environ Health (2006) 2.02
Insulin resistance alters islet morphology in nondiabetic humans. Diabetes (2013) 2.01
Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem (2002) 1.91
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol (2010) 1.85
Assessing EGFR mutations. N Engl J Med (2006) 1.83
ATM is activated by default in mitosis, localizes at centrosomes and monitors mitotic spindle integrity. Cell Cycle (2006) 1.82
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.79
Estrogen receptor-alpha and endothelial nitric oxide synthase nuclear complex regulates transcription of human telomerase. Circ Res (2008) 1.75
Metastases to the thyroid gland: prevalence, clinicopathological aspects and prognosis: a 10-year experience. Clin Endocrinol (Oxf) (2007) 1.74
Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. Blood (2009) 1.74
The interaction between a sexually transferred steroid hormone and a female protein regulates oogenesis in the malaria mosquito Anopheles gambiae. PLoS Biol (2013) 1.70
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat (2008) 1.64
Mutational profile of GNAQQ209 in human tumors. PLoS One (2009) 1.62
TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity. J Biol Chem (2003) 1.61
High telomerase activity in neutrophils from unstable coronary plaques. J Am Coll Cardiol (2007) 1.61
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer (2006) 1.55
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med (2007) 1.52
The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res (2006) 1.52
Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest (2009) 1.51
25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. Obesity (Silver Spring) (2010) 1.50
Rightward and leftward bisection biases in spatial neglect: two sides of the same coin? Brain (2007) 1.48
HIPK2: a multitalented partner for transcription factors in DNA damage response and development. Biochem Cell Biol (2007) 1.45
Evaluation of antioxidant systems (coenzyme Q10 and total antioxidant capacity) in morbid obesity before and after biliopancreatic diversion. Metabolism (2008) 1.44
Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord (2009) 1.43
Circulating endothelial cells as marker of endothelial damage in male hypogonadism. J Androl (2012) 1.42
Severe growth hormone deficiency and empty sella in obesity: a cross-sectional study. Endocrine (2015) 1.42
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest (2007) 1.41
Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone. Haematologica (2002) 1.39
A case of 45,X male: genetic reevaluation and hormonal and metabolic follow-up in adult age. Fertil Steril (2008) 1.38
Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell (2006) 1.38
Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle (2008) 1.36
Survivin gene expression in early-stage non-small cell lung cancer. J Pathol (2003) 1.35
Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain (2011) 1.35
Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene (2005) 1.35
Retracted High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest (2007) 1.34
Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res (2006) 1.33
microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol (2013) 1.31
Epigenetic histone modification and cardiovascular lineage programming in mouse embryonic stem cells exposed to laminar shear stress. Circ Res (2005) 1.29
Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem (2002) 1.29
Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord (2007) 1.28
Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res (2004) 1.25
Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch (2012) 1.24
The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J (2009) 1.23
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO J (2009) 1.23